Posted by Michael Wonder on 11 Oct 2024
Roche Canada announces Columvi (glofitamab for injection) is publicly reimbursed in 7 provinces, including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia and Newfoundland
9 October 2024 - Columvi is now publicly covered in 7 provinces, which equates to approximately 74% of the total Canadian population, and is the first and only fixed treatment duration bispecific antibody authorised in Canada to treat diffuse large B-cell lymphoma.
Roche Canada is pleased to announce today that Columvi (glofitamab for injection) is now publicly funded in 7 provinces, including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia and Newfoundland.
